Navigation Links
Sorafenib Slows Growth of Some Leukemias
Date:2/1/2008

Drug shows potential for patients with specific gene mutations, researchers find

FRIDAY, Feb. 1 (HealthDay News) -- The drug sorafenib shows promise in the treatment of people with acute myeloid leukemia who have specific gene mutations, say U.S. researchers.

Previous research has shown that sorafenib -- currently used to treat kidney and liver cancer -- is effective against acute myeloid leukemia cells that have internal tandem duplication (ITD) mutations of the Fms-like tyrosine kinase 3 (FLT3) gene, according to background information in the study.

Researchers at the University of Texas M.D. Anderson Cancer Center in Houston looked at sorafenib's effect on leukemia cells that express either the common or mutant copies of FLT3. They also gave the drug to mice with leukemia cells with known FLT3 mutations and to leukemia patients with and without the FLT3 mutation.

Sorafenib slowed growth and induced cell death in the FLT3 mutant leukemia cells and increased survival of the mice with FLT3 mutant leukemia. The drug also reduced the percentage of leukemia cells in the blood and marrow of leukemia patients with the FLT3 mutation but not in leukemia patients without the mutation.

"Our findings imply that sorafenib is a potent anti-leukemic agent in patients with FLT3-ITD mutant [acute myeloid leukemia], a form of [the disease] that responds poorly to traditional chemotherapy," the study authors concluded.

The findings were published in the Jan. 29 issue of the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about acute myeloid leukemia.



-- Robert Preidt



SOURCE:Journal of the National Cancer Institute, news release, Jan. 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Health Insurance Premium Growth Slows for Fourth Straight Year
2. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
3. Drug slows prostate tumor growth by keeping vitamin A active
4. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
5. High pollution linked to poor lung function growth in children in Mexico City
6. Researchers develop long-lasting growth hormone
7. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
8. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
9. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
10. AWT Management Announce Aggressive Growth and Acquisition Strategy
11. Cynosure to Present at the Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sorafenib Slows Growth of Some Leukemias
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: